

AMENDMENTS TO THE CLAIMS

This **listing of claims** will replace all prior versions, and listings, of the claims in the application.

Listing of Claims

1-144. (canceled)

145. (previously presented) A method of treating a transplant recipient or preventing transplant rejection in a transplant recipient, comprising administering to the recipient an effective amount of a humanized immunoglobulin specific to B7-1, and an effective amount of a immunoglobulin specific to B7-2, wherein the humanized immunoglobulin specific to B7-1 comprises a constant region of human origin and a variable region, wherein said variable region comprises:

- a) one or more complementarity determining regions derived from the 1F1 mouse monoclonal antibody (ATCC Accession No. PTA 263) and
- b) one or more framework regions of human origin.

146. (canceled)

147. (previously presented) The method of Claim 145, further comprising the step of administering cyclosporin A or FK506 to the recipient.

148. (canceled)

149. (previously presented) The method of Claim 145, further comprising the step of administering rapamycin to the recipient.

150. (previously presented) The method of Claim 145, wherein the immunoglobulin specific to B7-1 is administered in an amount between about 1 mg/kg and about 25 mg/kg, and the immunoglobulin specific to B7-2 is administered in an amount between about 1 mg/kg and about 25 mg/kg.

151. (previously presented) The method of Claim 150, wherein the immunoglobulin specific to B7-1 and the immunoglobulin specific to B7-2 are administered on the day the recipient receives the transplantation.

152. (previously presented) The method of Claim 149, wherein the humanized immunoglobulin specific to B7-1 and the immunoglobulin specific to B7-2 are further administered periodically after the recipient receives the transplantation.

153. (previously presented) The method of Claim 152, wherein the humanized immunoglobulin specific to B7-1 is administered between about 1 mg/kg and about 5 mg/kg, and the immunoglobulin specific to B7-2 is administered between about 1 mg/kg and about 5 mg/kg at least weekly after the recipient receives the transplantation.

154-160. (canceled)

161. **(currently amended)** The method of claim 145, wherein the immunoglobulin specific to B7-2 is a humanized immunoglobulin that has a binding affinity for B7-2 of at least about 10^7 M^{-1} , and wherein the immunoglobulin specific to B7-2 comprises an antigen binding region of non-human origin and at least a portion of an immunoglobulin of human origin, further wherein the antigen binding region of non-human origin comprises at least one framework region containing a substitution of at least one amino acid in the heavy chain framework region of the III2R antibody (SEQ ID NOS: 45, 49) ~~heavy chain framework region~~ or the light chain framework region of the H2F antibody (SEQ ID NOS: 46, 50) ~~light chain framework region~~.

162. **(currently amended)** A method of treating a transplant recipient or preventing transplant rejection in a transplant recipient, comprising administering to the recipient an effective amount of an immunoglobulin specific to B7-1, and an effective amount of a humanized immunoglobulin specific to B7-2, wherein the humanized immunoglobulin specific to B7-2 has a binding affinity of at least about 10^7 M^{-1} , and wherein said immunoglobulin comprises at least a portion of an immunoglobulin of human origin, further wherein the antigen binding region of non-human origin comprises at least one framework region containing a substitution of at least one amino acid to a corresponding amino acid in the heavy chain framework region of the III2R antibody (SEQ ID NOS: 45, 49) or the light chain framework region of the H2F antibody (SEQ ID NOS: 46, 50), ~~and wherein treatment of the autoimmune disease occurs.~~

163. (previously presented) The method of Claim 162, further comprising the step of administering cyclosporin A or FK506 to the recipient.

164. (previously presented) The method of Claim 145, further comprising the step of administering rapamycin to the recipient.